J&J touts long list of advanced drug candidates

The Wall Street Journal reports that Johnson & Johnson has been touting a fattened drug pipeline to Wall Street. The drug giant has told analysts that it has 17 drugs that are either in advanced clinical trials or awaiting approval. Four years ago in its last Wall Street review the company had two advanced drugs. Among its most promising candidates are dapoxetine for premature ejaculation, the antipsychotic paliperidone and Yondelis. Johnson & Johnson has also set its sites on supplying drugs for HIV/AIDS.

- read this story from AFX for more on the pipeline

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.